Rationally engineered Losmapimod encapsulating polymeric nanoparticles for treatment of human multiple myeloma cells

• DOI: 10.1007/s13204-021-02010-3
• Publication Date: 2021-09-21T12:27:59Z
• Authors: Shuting Ye; Zhengjun Hou; Yayun Su; Miya Ye; Tairan Liu; Weiwei Ying; Meiyun Su
• Keywords: 0301 basic medicine; 03 medical and health sciences; 3. Good health

Human multiple myeloma is an incurability of haematological cancer with recurrence rates above 90%. For the successful use of chemotherapy in MM, the critical limiting factor is the severe adverse effects of this drug. The anticancer efficiency of Losmapimod encapsulated in poly(lactic-co-glycolic acid) nanoparticles (LOS@PLGA-NPs) in vitro using multiple myeloma cells has been established. Furthermore, the morphological examination, hydrodynamic size and zeta potential of the nanoparticle were examined by the high-resolution transmission electron microscopy and dynamic light scattering method. The Cell Counting Kit-8 analysis has shown a significant inhibitory impact of LOS@PLGA-NPs on MM cancer cells (U266 and IM9). Furthermore, an investigation of the mechanism showed that apoptosis in cancer cells has performed by anticancer activity. We also demonstrated that such drugs showed promise antimetastatic efficacy and inhibited cancer cell invasiveness. Importantly, LOS@PLGA-NPs have confirmed to indicate that the dramatically better animal safety profile of the LOS is highlighted as prospective candidates for MM cancer treatment using these LOS@PLGA-NPs and deserve further evaluation.